WellSaid Expands AI Voice Offering with Lowest-Cost API and Revenue-Ready Partner Program
SEATTLE--(BUSINESS WIRE)-- WellSaid, the AI voice platform trusted by leading enterprise teams, today announced a major upgrade to its developer API, combining premium-quality AI voice with unmatched control and the lowest pricing among AI Voice providers. With this launch, product and engineering teams can now build ultra-realistic voice experiences faster, with full programmatic control and costs reduced by up to 50%.
As a joint initiative with the new API, the company also introduced the WellSaid Partner Program to deliver both technical advancements and additional support for customers. The program will help enterprise organizations and ecosystem partners integrate WellSaid's API into their products and go to market with co-selling support, early product access, and preferred pricing.
'Developers are under pressure to move fast, stay flexible, and deliver polished experiences without blowing the budget,' said Chris Johnson, Chief Technology and Product Officer of WellSaid. 'We built our API to meet those realities — high-quality voice, full control, and faster implementation, all at half the cost of other providers. With the new Partner Program, we're helping teams go further by turning that capability into a growth engine.'
A cost-quality breakthrough for developers
The WellSaid API is purpose-built for real-time applications, high-volume content pipelines, and full customization. Key capabilities include:
Ultra-realistic voices powered by WellSaid's proprietary Caruso model
Fine-tuned control over pitch, speed, pausing, pronunciation, and tone
Low-latency, streaming, and high concurrency for responsive performance
Support for long-form content like audiobooks, eLearning, and scripted media
Commercial rights included, with SOC 2, GDPR, and EU AI Act compliance
1 million characters per month while users are building
Teams use the API across a wide range of use cases, from IVR systems, virtual assistants, and chatbots to audiobooks, marketing campaigns, accessibility tools, and in-game character voices.
New partner program supports growth and monetization
The WellSaid Partner Program is designed for teams embedding AI voice into their platforms or delivering it to clients. The program offers:
Preferred subscription pricing for client accounts
Revenue opportunities through co-marketing and co-selling
Early access to new API features and integrations
Workshops and GTM enablement with WellSaid's partner team
Dedicated support from Partner Managers, CSMs, and AEs
Partner tiers available for startups, agencies, and technology providers.
The WellSaid Partner Program includes companies like MNTN (NYSE: MNTN), a technology platform that brings performance marketing to Connected TV, and TRIPP, an AI-powered mental wellness platform. One early partner, Everlit, is already seeing results in the fast-moving news and media space.
'We are thrilled to be a partner with WellSaid, and working with them has been wonderful. As a rapidly growing partner in the news and media space, we needed a partner who could be both reliable and responsive. At this stage, they've delivered on both,' said Evan Woolley, Co-Founder of Everlit.
WellSaid's proprietary AI models are trained on exclusive and licensed voice data. Every voice is production-ready and commercially cleared for public or client-facing content. The platform is trusted by Fortune 500 brands including LinkedIn, T-Mobile, ServiceNow, and Accenture.
To learn more about WellSaid's text-to-speech API and sign up for a free trial, visit www.wellsaid.io/products/api. For more information about joining WellSaid's Partner Program, visit www.wellsaid.io/products/api-partner-page.
About WellSaid
WellSaid is an advanced AI voice platform that transforms text into natural-sounding speech. Using proprietary AI models trained on exclusive and licensed voice data, WellSaid creates authentic voiceovers with diverse accents, dialects, and languages. Designed for applications like corporate training, advertising, video production, publishing, and audiobooks, WellSaid simplifies audio content creation across industries. Built with a closed-source model and responsible AI practices, WellSaid is trusted by Fortune 500 companies, including LinkedIn, T-Mobile, ServiceNow, and Accenture. For more information, visit wellsaid.io.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
30 minutes ago
- Business Wire
Pharmaceuticals and Biotechnology Option and Evaluation Agreements Analysis Report 2025 with Directory of Deals Signed Since 2019 - Upfront, Royalty, Milestone Financials
DUBLIN--(BUSINESS WIRE)--The "Option and Evaluation Deals in Pharmaceuticals and Biotechnology 2019-2025" has been added to offering. This report contains a comprehensive listing of option and evaluation deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual option and evaluation contract documents as submitted to the Securities Exchange Commission by companies and their partners. Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter option and evaluation deals. Fully revised and updated, the report provides details of option and evaluation deals from 2019 to 2025. The report provides access to option and evaluation deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not. The initial chapters of this report provide an orientation of option and evaluation dealmaking and business activities. Chapter 1 introduces the report, followed by Chapter 2 which offers an overview and analysis of the trends in option and evaluation deals, alongside discussing the merits of such deals. Chapter 3 details the structure of option and evaluation deals, while Chapter 4 reviews the leading deals since 2019, ordered by headline value. Chapter 5 lists the top 25 active dealmakers with available links to full records and contracts, and Chapter 6 provides an organized review of deals by company, therapy, technology, and industry type, offering insights into agreed terms. Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits: Understand deal trends since 2019 Browse option and evaluation deals Benchmark analysis - identify market value of transactions Financials terms Directory of deals by company A-Z, therapy focus and technology type Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in option and evaluation dealmaking 2.1. Introduction 2.2. Definition of option and evaluation deal 2.3. Trends in option and evaluation deals since 2019 2.3.1. Option and evaluation dealmaking by year, 2019-2025 2.3.2. Option and evaluation dealmaking by phase of development, 2019-2025 2.3.3. Option and evaluation dealmaking by industry sector, 2019-2025 2.3.4. Option and evaluation dealmaking by therapy area, 2019-2025 2.3.5. Option and evaluation dealmaking by technology type, 2019-2025 2.3.6. Option and evaluation dealmaking by most active company, 2019-2025 2.4. Reasons for entering into option and evaluation partnering deals 2.5. The future of option and evaluation deals Chapter 3 - Overview of option and evaluation deal structure 3.1. Introduction 3.2. Option and evaluation agreement structure Chapter 4 - Leading option and evaluation deals 4.1. Introduction 4.2. Top option and evaluation deals by value Chapter 5 - Top 25 most active option and evaluation dealmakers 5.1. Introduction 5.2. Top 25 most active option and evaluation dealmakers Chapter 6 - option and evaluation deals including contracts directory 6.1. Introduction 6.2. Option and evaluation deals with contracts 2019-2025 Deal directory Deal directory - option and evaluation dealmaking by companies A-Z Deal directory - option and evaluation dealmaking by therapy area Deal directory - option and evaluation dealmaking by technology type For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Yahoo
an hour ago
- Yahoo
Lazard Global Total Return and Income Fund Declares Monthly Distribution and Issues Estimated Sources of the Distribution Announced in May
NEW YORK, June 24, 2025--(BUSINESS WIRE)--Lazard Global Total Return and Income Fund, Inc. (the "Fund") (NYSE:LGI) is confirming today, pursuant to its Managed Distribution Policy, as previously authorized by its Board of Directors, a monthly distribution of $0.14646 per share on the Fund's outstanding common stock. The distribution is payable on July 22, 2025 to shareholders of record on July 10, 2025. The ex-dividend date is July 10, 2025. The Fund will pay a previously declared distribution today, June 24, 2025. The following table sets forth the estimated amounts of the current distribution and the cumulative distributions paid, including today's distribution, from the following sources: net investment income, net realized capital gains (short-term and long-term), and return of capital. All amounts are expressed per share of common stock and are based on accounting principles generally accepted in the US, which may differ from federal income tax regulations. Current Distribution % of the CurrentDistribution Total CumulativeDistributions for theFiscal Year to Date % of the Total CumulativeDistributions for the FiscalYear to Date Net Income $0.06371 43% $0.06371 7% Net Realized Short-Term Capital Gains $0.00375 3% $0.02250 3% Net Realized Long-Term Capital Gains $0.00025 0% $0.25018 28% Return of Capital $0.07875 54% $0.54237 62% Total $0.14646 100% $0.87876 100% Average annual total return (in relation to NAV) for the 5-year period ending on May 31, 2025 10.39% Annualized current distribution rate expressed as a percentage of NAV as of May 31, 2025 10.09% Cumulative total return (in relation to NAV) for the fiscal year through May 31, 2025 3.27% Cumulative fiscal year distributions as a percentage of NAV as of May 31, 2025 4.21% You should not draw any conclusions about the Fund's investment performance from the amount of this distribution or from the terms of the Fund's Managed Distribution Policy. The Fund estimates that it has distributed more than its net investment income and net realized capital gains; therefore, a portion of your distribution may be return of capital. A return of capital may occur, for example, when some or all of the money that you invested in the Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund's investment performance and should not be confused with "yield" or "income". The amounts and sources of distributions reported above are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund's investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund provides financial intermediary firms the information necessary to produce the Form 1099-DIV, and then the relevant financial intermediary firm will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes. If you have any questions, or need additional information, please call us at 1-800-823-6300. Portfolio data as of May 31, 2025, including performance, asset allocation, top 10 holdings, sector weightings, regional exposure, and other Fund characteristics have been posted on Lazard Asset Management's ("LAM") website, The Fund's investment objective is total return, consisting of capital appreciation and current income. The Fund's net assets are invested in a portfolio of approximately 60 to 80 US and non-US equity securities, including American Depository Receipts, generally of companies with market capitalizations greater than $2 billion, and may include investments in emerging markets. The Fund also invests in emerging market currencies (primarily by entry into forward currency contracts), or instruments whose value is derived from the performance of an underlying emerging market currency, and also may invest in debt obligations, including government, government agency and corporate obligations and structured notes denominated in emerging market currencies. An indirect subsidiary of Lazard, Inc. (NYSE: LAZ), LAM, the Fund's investment manager, offers a range of equity, fixed-income, and alternative investment products worldwide. As of May 31, 2025, LAM and affiliated asset management companies in the Lazard Group managed $235.3 billion worth of client assets. For more information about LAM, please go to Follow LAM at @LazardAsset. View source version on Contacts Media contact:Aziz Nayani, +1 212 632 Investor contact:Ben Wulfsohn, +1 800 823 Sign in to access your portfolio
Business Wire
an hour ago
- Business Wire
Lazard Global Total Return and Income Fund Declares Monthly Distribution and Issues Estimated Sources of the Distribution Announced in May
NEW YORK--(BUSINESS WIRE)--Lazard Global Total Return and Income Fund, Inc. (the "Fund") (NYSE:LGI) is confirming today, pursuant to its Managed Distribution Policy, as previously authorized by its Board of Directors, a monthly distribution of $0.14646 per share on the Fund's outstanding common stock. The distribution is payable on July 22, 2025 to shareholders of record on July 10, 2025. The ex-dividend date is July 10, 2025. The Fund will pay a previously declared distribution today, June 24, 2025. The following table sets forth the estimated amounts of the current distribution and the cumulative distributions paid, including today's distribution, from the following sources: net investment income, net realized capital gains (short-term and long-term), and return of capital. All amounts are expressed per share of common stock and are based on accounting principles generally accepted in the US, which may differ from federal income tax regulations. Average annual total return (in relation to NAV) for the 5-year period ending on May 31, 2025 10.39% Annualized current distribution rate expressed as a percentage of NAV as of May 31, 2025 10.09% Cumulative total return (in relation to NAV) for the fiscal year through May 31, 2025 3.27% Cumulative fiscal year distributions as a percentage of NAV as of May 31, 2025 4.21% Expand You should not draw any conclusions about the Fund's investment performance from the amount of this distribution or from the terms of the Fund's Managed Distribution Policy. The Fund estimates that it has distributed more than its net investment income and net realized capital gains; therefore, a portion of your distribution may be return of capital. A return of capital may occur, for example, when some or all of the money that you invested in the Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund's investment performance and should not be confused with "yield" or "income". The amounts and sources of distributions reported above are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund's investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund provides financial intermediary firms the information necessary to produce the Form 1099-DIV, and then the relevant financial intermediary firm will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes. If you have any questions, or need additional information, please call us at 1-800-823-6300. Portfolio data as of May 31, 2025, including performance, asset allocation, top 10 holdings, sector weightings, regional exposure, and other Fund characteristics have been posted on Lazard Asset Management's ("LAM") website, The Fund's investment objective is total return, consisting of capital appreciation and current income. The Fund's net assets are invested in a portfolio of approximately 60 to 80 US and non-US equity securities, including American Depository Receipts, generally of companies with market capitalizations greater than $2 billion, and may include investments in emerging markets. The Fund also invests in emerging market currencies (primarily by entry into forward currency contracts), or instruments whose value is derived from the performance of an underlying emerging market currency, and also may invest in debt obligations, including government, government agency and corporate obligations and structured notes denominated in emerging market currencies. An indirect subsidiary of Lazard, Inc. (NYSE: LAZ), LAM, the Fund's investment manager, offers a range of equity, fixed-income, and alternative investment products worldwide. As of May 31, 2025, LAM and affiliated asset management companies in the Lazard Group managed $235.3 billion worth of client assets. For more information about LAM, please go to Follow LAM at @LazardAsset.
